The information in the press release is intended for investors.

Isofol enters collaboration with Lonza to develop a new spray dried formulation of arfolitixorin for cerebral folate deficiency

GOTHENBURG, Sweden, November 26, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company has signed a collaboration agreement with the contract manufacturing organization Lonza to develop a new formulation of arfolitixorin. The collaboration aims to develop a user-friendly method of administration for use in the exploratory development of a treatment for cerebral folate deficiency (CFD), reported in some people with autism.

Isofol is developing arfolitixorin – a proprietary clinical-stage, folate-based drug candidate designed to enhance the efficacy of established cancer treatments. The company is currently conducting a phase Ib/II clinical trial in metastatic colorectal cancer and, in parallel, carrying out an exploratory preclinical project to evaluate the potential of arfolitixorin in the treatment of cerebral folate deficiency (CFD). CFD is a neurological condition that affects folate (essential for brain health) transport into the brain which can cause severe developmental delays with autistic features and other serious neurological complications.

Following the observation that folate-based therapies may have a positive effect in a subgroup of children and adults with autism who have CFD, the U.S. Food and Drug Administration (FDA) in March 2026 approved the use of a folate-based medication, leucovorin, for the treatment of patients with a confirmed folate receptor 1 gene variant (CFD-FOLR1). In March 2026, Isofol secured expanded licensing rights and filed a patent application for arfolitixorin for the treatment of CFD. Since then, exploratory preclinical research has been underway to evaluate its potential in this area.

The current formulation of arfolitixorin, which is administered intravenously, is optimized for cancer treatment and is less suitable for treating CFD. Isofol and Lonza now aim to develop a new formulation of arfolitixorin designed to make administration easier and improve delivery of the drug to the brain. Isofol will provide the active pharmaceutical ingredient (API), while Lonza will evaluate the development of a spray dried formulation.

"Our primary focus remains on improving current and future cancer treatment, and our ongoing phase Ib/II clinical trial in metastatic colorectal cancer has shown promising results to date. In parallel, we are evaluating opportunities to potentially expand into other indications where we believe arfolitixorin could benefit patients. The collaboration with Lonza is currently small-scale and exploratory in nature but could open the door to an entirely new therapeutic area, and we look forward to exploring these opportunities," says Petter Segelman Lindqvist, CEO of Isofol.

For further information, please contact

Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0)739 60 12 56

The information was submitted for publication, through the agency of the contact persons listed above, on 26 November 2026 at 08:00 CET.

About Isofol

Isofol Medical AB (publ) is a clinical stage biotechnology company focused on improving outcomes for patients with severe forms of cancer. The company's drug candidate arfolitixorin, a next generation folate treatment, is designed to enhance the efficacy of established standard treatments for several types of solid tumors. Arfolitixorin is currently being evaluated in phase Ib/II in colorectal cancer, the world's third most common cancer, where there is a significant unmet medical need. Isofol is listed on Nasdaq Stockholm.

www.isofolmedical.com